FOSTER CITY, Calif.--(BUSINESS WIRE)--Sep. 26, 2019--
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that company management will present an overview of the company at the Cantor 2019 Global Healthcare Conference.
Location: New York, NY
Presentation date: Friday October 4, 2019
Presentation time: 10:40 a.m. ET
A live audio webcast and archive of the presentation will be available at http://ir.mirumpharma.com
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS). For more information, visit MirumPharma.com. Follow Mirum on Twitter, Facebook and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190926005227/en/
Source: Mirum Pharmaceuticals, Inc.
Heidi Chokeir, Ph.D.
Ian Clements, Ph.D.